mRNA cancer vaccine delays melanoma return in phase 3 trial
Merck and Moderna say their personalized mRNA vaccine plus Keytruda delayed melanoma recurrence in 1,137 patients after surgery, the first positive phase 3 result for an mRNA cancer therapy, though no effect sizes have been released.




